5 burning questions for an Asian bioventure CEO
This article was originally published in Scrip
Executive Summary
Singapore-based ASLAN Pharmaceuticals is developing a small pipeline of molecules for oncology and inflammatory disorders, tapping into Asia's high-quality clinical infrastructure to rapidly take projects to proof-of-concept for subsequent partnering for regional and global markets. The venture, set up in 2010, closed a Series B financing last October, raising $22m (scripintelligence.com, 10 October 2013).
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Merck & Co progresses cardiovascular strategy; Novo purchase builds heart failure presence; CRL setbacks for Regeneron; ITF faces challenging Duchenne field; and AbbVie needs to freshen up.